NTLA

#2074
Intellia Therapeutics, Inc
14.7800 USD
+3.65%
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
14.7800
14.7800
Годовой диапазон
7.9500
17.0900
Дневное изменение
+3.65%
Месячное изменение
+12.65%
6-месячное изменение
+7.73%
Годовое изменение
+7.73%
Предыдущее закрытие
14.2600
Открыть
14.7800
Bid
Ask
Минимум
14.7800
High
14.7800
Объем
95
Открыть полный график

Financials

Обзор Отчетность Статистика
Квартал Год
  • Market Capitalization 1.746 B
  • Employee 377
  • Founded 2014
  • CEO John Leonard
  • Website www.intelliatx.com
  • Headquarter Delaware, United States
  • FIGI BBG007KC7PB0
  • Industry Technology
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
-2.36
Коэффициент цена/денежный поток
14.4

Intellia Therapeutics Inc

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies.

Новости